Targeting mTOR pathways in human malignancies
- PMID: 22475451
- DOI: 10.2174/138161212800626210
Targeting mTOR pathways in human malignancies
Abstract
Background: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the phosphatidylinositol 3-Kinase (PI3K)/AKT signalling pathway with a central role in the control of cell growth, survival and angiogenesis. Multiple and frequent dysregulations of this pathway in human tumors make it a central target in the development of new anticancer treatments.
Objective: To review the most significant data on mTOR pathway, role of mTOR inhibitors in cancer treatment, preclinical and clinical data of the three first generation mTOR inhibitors (temsirolimus, everolimus and deferolimus), rationales, preclinical and clinical data of second generation mTOR inhibitors.
Methods: Review of published literature on mTOR and related pathways, rapalogs and novel mTOR inhibitors.
Results/conclusions: Temsirolimus and everolimus have been approved for the treatment of metastatic Renal Cell Carcinoma (RCC), temsirolimus also for Mantle Cell Lymphoma (MCL) and everolimus will be approved for pancreatic neuroendocrine tumors; all three rapalogs are currently evaluated in phase III studies in several tumors. Only limited published data are available on new mTOR inhibitors; however, in vitro and in vivo in preclinical studies they have shown a significant antiproliferative activity against a broad panel of tumors and a favourable safety profile, with disease stabilization or even tumor regression, either as single agent or in combination.
Similar articles
-
Current and future directions in mammalian target of rapamycin inhibitors development.Expert Opin Investig Drugs. 2011 Mar;20(3):381-94. doi: 10.1517/13543784.2011.541154. Epub 2011 Feb 8. Expert Opin Investig Drugs. 2011. PMID: 21299441 Review.
-
mTOR signaling and drug development in cancer.Nat Rev Clin Oncol. 2010 Apr;7(4):209-19. doi: 10.1038/nrclinonc.2010.21. Epub 2010 Mar 16. Nat Rev Clin Oncol. 2010. PMID: 20234352 Review.
-
Mammalian target of rapamycin: biological function and target for novel anticancer agents.Am J Health Syst Pharm. 2010 Dec 15;67(24):2095-106. doi: 10.2146/ajhp100020. Am J Health Syst Pharm. 2010. PMID: 21116000 Review.
-
m-TOR inhibitors and their potential role in haematological malignancies.Br J Haematol. 2017 Jun;177(5):684-702. doi: 10.1111/bjh.14529. Epub 2017 Feb 1. Br J Haematol. 2017. PMID: 28146265 Review.
-
Therapeutic targets: MTOR and related pathways.Cancer Biol Ther. 2006 Sep;5(9):1065-73. doi: 10.4161/cbt.5.9.3175. Epub 2006 Sep 6. Cancer Biol Ther. 2006. PMID: 16969122 Review.
Cited by
-
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.Front Pharmacol. 2018 Nov 13;9:1300. doi: 10.3389/fphar.2018.01300. eCollection 2018. Front Pharmacol. 2018. PMID: 30483135 Free PMC article. Review.
-
The true colors of autophagy in doxorubicin-induced cardiotoxicity.Oncol Lett. 2019 Sep;18(3):2165-2172. doi: 10.3892/ol.2019.10576. Epub 2019 Jul 5. Oncol Lett. 2019. PMID: 31452719 Free PMC article. Review.
-
Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer.Int J Mol Sci. 2020 Feb 11;21(4):1199. doi: 10.3390/ijms21041199. Int J Mol Sci. 2020. PMID: 32054043 Free PMC article. Review.
-
Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.Oncotarget. 2014 Aug 30;5(16):6788-800. doi: 10.18632/oncotarget.2253. Oncotarget. 2014. PMID: 25216518 Free PMC article.
-
New function of type I IFN: induction of autophagy.J Interferon Cytokine Res. 2014 Feb;34(2):71-8. doi: 10.1089/jir.2013.0128. Epub 2014 Jan 15. J Interferon Cytokine Res. 2014. PMID: 24428799 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
